vs
Insulet Corporation（PODD）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
利氏兄弟拍卖行的季度营收约是Insulet Corporation的1.5倍（$1.2B vs $783.7M），Insulet Corporation净利率更高（13.0% vs 9.1%，领先3.8%），Insulet Corporation同比增速更快（31.2% vs 5.4%），利氏兄弟拍卖行自由现金流更多（$186.5M vs $48.2M），过去两年Insulet Corporation的营收复合增速更高（33.2% vs 6.3%）
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
PODD vs RBA — 直观对比
营收规模更大
RBA
是对方的1.5倍
$783.7M
营收增速更快
PODD
高出25.7%
5.4%
净利率更高
PODD
高出3.8%
9.1%
自由现金流更多
RBA
多$138.3M
$48.2M
两年增速更快
PODD
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $783.7M | $1.2B |
| 净利润 | $101.6M | $109.7M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 18.7% | 14.7% |
| 净利率 | 13.0% | 9.1% |
| 营收同比 | 31.2% | 5.4% |
| 净利润同比 | 0.9% | -7.4% |
| 每股收益（稀释后） | $1.42 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PODDRBA
| Q4 25 | $783.7M | $1.2B | ||
| Q3 25 | $706.3M | $1.1B | ||
| Q2 25 | $649.1M | $1.2B | ||
| Q1 25 | $569.0M | $1.1B | ||
| Q4 24 | $597.5M | $1.1B | ||
| Q3 24 | $543.9M | $981.8M | ||
| Q2 24 | $488.5M | $1.1B | ||
| Q1 24 | $441.7M | $1.1B |
净利润PODDRBA
| Q4 25 | $101.6M | $109.7M | ||
| Q3 25 | $87.6M | $95.5M | ||
| Q2 25 | $22.5M | $109.8M | ||
| Q1 25 | $35.4M | $113.4M | ||
| Q4 24 | $100.7M | $118.5M | ||
| Q3 24 | $77.5M | $76.1M | ||
| Q2 24 | $188.6M | $111.1M | ||
| Q1 24 | $51.5M | $107.4M |
毛利率PODDRBA
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | — | ||
| Q1 24 | 69.5% | — |
营业利润率PODDRBA
| Q4 25 | 18.7% | 14.7% | ||
| Q3 25 | 16.7% | 14.5% | ||
| Q2 25 | 18.7% | 15.9% | ||
| Q1 25 | 15.6% | 17.1% | ||
| Q4 24 | 18.3% | 18.1% | ||
| Q3 24 | 16.2% | 15.6% | ||
| Q2 24 | 11.2% | 18.4% | ||
| Q1 24 | 12.9% | 18.7% |
净利率PODDRBA
| Q4 25 | 13.0% | 9.1% | ||
| Q3 25 | 12.4% | 8.7% | ||
| Q2 25 | 3.5% | 9.3% | ||
| Q1 25 | 6.2% | 10.2% | ||
| Q4 24 | 16.9% | 10.4% | ||
| Q3 24 | 14.2% | 7.8% | ||
| Q2 24 | 38.6% | 10.1% | ||
| Q1 24 | 11.7% | 10.1% |
每股收益（稀释后）PODDRBA
| Q4 25 | $1.42 | $0.53 | ||
| Q3 25 | $1.24 | $0.43 | ||
| Q2 25 | $0.32 | $0.53 | ||
| Q1 25 | $0.50 | $0.55 | ||
| Q4 24 | $1.38 | $0.58 | ||
| Q3 24 | $1.08 | $0.36 | ||
| Q2 24 | $2.59 | $0.54 | ||
| Q1 24 | $0.73 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $531.5M |
| 总债务越低越好 | $930.8M | $2.3B |
| 股东权益账面价值 | $1.5B | $5.6B |
| 总资产 | $3.2B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.61× | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资PODDRBA
| Q4 25 | — | $531.5M | ||
| Q3 25 | — | $674.7M | ||
| Q2 25 | — | $710.2M | ||
| Q1 25 | — | $578.1M | ||
| Q4 24 | — | $533.9M | ||
| Q3 24 | — | $650.7M | ||
| Q2 24 | — | $599.5M | ||
| Q1 24 | — | $462.8M |
总债务PODDRBA
| Q4 25 | $930.8M | $2.3B | ||
| Q3 25 | $934.9M | $2.6B | ||
| Q2 25 | $939.0M | $2.6B | ||
| Q1 25 | $1.6B | $2.6B | ||
| Q4 24 | $1.3B | $2.6B | ||
| Q3 24 | $1.4B | $2.7B | ||
| Q2 24 | $1.4B | $2.8B | ||
| Q1 24 | $1.4B | $2.9B |
股东权益PODDRBA
| Q4 25 | $1.5B | $5.6B | ||
| Q3 25 | $1.4B | $5.5B | ||
| Q2 25 | $1.5B | $5.5B | ||
| Q1 25 | $1.3B | $5.3B | ||
| Q4 24 | $1.2B | $5.2B | ||
| Q3 24 | $1.1B | $5.2B | ||
| Q2 24 | $998.4M | $5.2B | ||
| Q1 24 | $790.7M | $5.1B |
总资产PODDRBA
| Q4 25 | $3.2B | $12.1B | ||
| Q3 25 | $3.0B | $12.2B | ||
| Q2 25 | $3.5B | $12.2B | ||
| Q1 25 | $3.5B | $11.9B | ||
| Q4 24 | $3.1B | $11.8B | ||
| Q3 24 | $3.0B | $11.9B | ||
| Q2 24 | $2.9B | $12.1B | ||
| Q1 24 | $2.6B | $12.0B |
负债/权益比PODDRBA
| Q4 25 | 0.61× | 0.42× | ||
| Q3 25 | 0.68× | 0.47× | ||
| Q2 25 | 0.64× | 0.47× | ||
| Q1 25 | 1.21× | 0.50× | ||
| Q4 24 | 1.07× | 0.50× | ||
| Q3 24 | 1.21× | 0.52× | ||
| Q2 24 | 1.36× | 0.55× | ||
| Q1 24 | 1.72× | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.3M | $255.2M |
| 自由现金流经营现金流 - 资本支出 | $48.2M | $186.5M |
| 自由现金流率自由现金流/营收 | 6.2% | 15.5% |
| 资本支出强度资本支出/营收 | 17.2% | 5.7% |
| 现金转化率经营现金流/净利润 | 1.80× | 2.33× |
| 过去12个月自由现金流最近4个季度 | $377.7M | $719.2M |
8季度趋势，按日历期对齐
经营现金流PODDRBA
| Q4 25 | $183.3M | $255.2M | ||
| Q3 25 | $125.7M | $239.7M | ||
| Q2 25 | $196.5M | $326.5M | ||
| Q1 25 | $63.8M | $156.8M | ||
| Q4 24 | $147.7M | $184.5M | ||
| Q3 24 | $98.5M | $285.4M | ||
| Q2 24 | $96.5M | $337.3M | ||
| Q1 24 | $87.6M | $124.8M |
自由现金流PODDRBA
| Q4 25 | $48.2M | $186.5M | ||
| Q3 25 | $100.1M | $188.5M | ||
| Q2 25 | $177.9M | $241.7M | ||
| Q1 25 | $51.5M | $102.5M | ||
| Q4 24 | $94.1M | $127.9M | ||
| Q3 24 | $71.8M | $248.5M | ||
| Q2 24 | $74.0M | $308.6M | ||
| Q1 24 | $65.5M | $79.6M |
自由现金流率PODDRBA
| Q4 25 | 6.2% | 15.5% | ||
| Q3 25 | 14.2% | 17.3% | ||
| Q2 25 | 27.4% | 20.4% | ||
| Q1 25 | 9.1% | 9.2% | ||
| Q4 24 | 15.7% | 11.2% | ||
| Q3 24 | 13.2% | 25.3% | ||
| Q2 24 | 15.1% | 28.2% | ||
| Q1 24 | 14.8% | 7.5% |
资本支出强度PODDRBA
| Q4 25 | 17.2% | 5.7% | ||
| Q3 25 | 3.6% | 4.7% | ||
| Q2 25 | 2.9% | 7.2% | ||
| Q1 25 | 2.2% | 4.9% | ||
| Q4 24 | 9.0% | 5.0% | ||
| Q3 24 | 4.9% | 3.8% | ||
| Q2 24 | 4.6% | 2.6% | ||
| Q1 24 | 5.0% | 4.2% |
现金转化率PODDRBA
| Q4 25 | 1.80× | 2.33× | ||
| Q3 25 | 1.43× | 2.51× | ||
| Q2 25 | 8.73× | 2.97× | ||
| Q1 25 | 1.80× | 1.38× | ||
| Q4 24 | 1.47× | 1.56× | ||
| Q3 24 | 1.27× | 3.75× | ||
| Q2 24 | 0.51× | 3.04× | ||
| Q1 24 | 1.70× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
